Omada Health (OMDA) Insider Adam Stavisky Buys 10,882 Shares

Adam Stavisky made a move in the stock market by purchasing 10,882 shares of Omada Health, Inc. (NasdaqGS: OMDA) on June 16, 2026. While the transaction didn't have a specified purchase price, the stock was trading at $17.25 at the time.

What Changed in Adam Stavisky's Omada Health Position

Adam Stavisky's acquisition of 10,882 shares of Omada Health represents a direct purchase, as noted in the transaction records. This insider buy was not part of a pre-planned trading program, indicating a personal decision to increase his stake in the company.

Other Institutional Activity in Omada Health

In recent institutional activity, Divisadero Street Capital Management, LP significantly increased its holdings in Omada Health by 5,418,118 shares, bringing its total to 5,887,715 shares, valued at about $74 million. Revelation Capital Management, LLC held steady with 5,208,034 shares worth approximately $65.5 million. Meanwhile, FMR LLC reduced its position by 1,890,124 shares, leaving it with 3,288,380 shares valued at around $41.3 million.

Omada Health, Inc. Stock Down 15.6%

Shares of Omada Health are currently trading around $17.25. The company boasts a market capitalization of approximately $1.03 billion and has a forward P/E ratio of 36.2. The stock's 52-week range spans from a low of $10.28 to a high of $26.92. Omada Health maintains a healthy current ratio of 3.92 and a quick ratio of 3.69, indicating solid liquidity.

Recent Earnings

Omada Health reported revenue of $283.3 million, reflecting a growth rate of 42%. However, the company posted a net margin of -2.22% and a return on equity of -4.30%, indicating some financial challenges. Investors will be looking forward to the next earnings release on August 6, 2026.

Insider Buying and Selling at Omada Health, Inc.

In addition to Adam Stavisky's purchase, several other insiders, including Jain Sachin, Jonathan Root, Anne Beal, Jeryl Hilleman, and Trevor Fetter, each acquired 10,882 shares on the same day. These transactions were not part of pre-planned trading programs.

Analysts Set New Price Targets

On May 8, 2026, Barclays maintained its buy rating on Omada Health with a price target of $20. Similarly, Citizens maintained a buy rating with a target of $21. Evercore ISI Group also kept a buy rating with a target of $20, while Wells Fargo maintained a hold rating with an $18 target. Overall, the stock has a consensus buy rating from 12 analysts, with a mean target price of about $22.92.

About Omada Health, Inc.

Omada Health, Inc. offers a variety of virtual care programs aimed at improving health outcomes. Its services include programs for managing prediabetes, diabetes, and hypertension, as well as physical therapy and behavioral health support. The company serves employers, health plans, and pharmacy benefits managers through direct sales and partnerships. Headquartered in South San Francisco, California, Omada Health is led by CEO Sean P. Duffy and employs 943 people.

Bottom Line

Adam Stavisky's recent purchase of Omada Health shares highlights insider confidence in the company's potential. With a diverse range of virtual health programs and a solid market presence, Omada Health remains a key player in the healthcare sector. Investors will watch closely for the upcoming earnings report in August 2026, as well as any further insider activity or analyst updates.